ROIV Stock Summary and Trading Ideas (Roivant Sciences Ltd. - Common Shares | NASDAQ:ROIV)

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.

As of April 9, 2025, ROIV stock price climbed to $9.59 with 4,749,189 million shares trading.

ROIV has a beta of 0.85, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.22 to the broad based SPY ETF.

ROIV has a market cap of $6.84 billion. This is considered a Mid Cap stock.

Last quarter Roivant Sciences Ltd. - Common Shares reported $9 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.04.

In the last 3 years, ROIV traded as high as $13.24 and as low as $2.52.

The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, VB, IJH, VBK, VXF.

ROIV has underperformed the market in the last year with a price return of -17.5% while the SPY ETF gained +3.5%. ROIV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.0% and -10.1%, respectively, while the SPY returned -9.9% and -8.0%, respectively.

ROIV support price is $8.85 and resistance is $9.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.